Pure Global
NCT03859752

TR1801-ADC in Patients With Tumors That Express c-Met

A Phase 1, Open Label, First-in-human Study of TR1801-ADC, an Antibody Drug Conjugate (ADC), in Patients With Select Solid Tumors Expressing c-Met
Tanabe Research Laboratories USA Inc·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
TR1801-ADC
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Tanabe Research Laboratories USA Inc
Location
Los Angeles,Newport Beach,Aurora,Baltimore,Seattle, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Aug 14, 2019
End date
Mar 31, 2023
Enrollment
40 participants
Primary outcome

Characterize safety of TR1801-ADC in patients with advanced solid tumor malignancies which express c-Met,Establish maximum tolerated dose

Summary

First-in-human, Phase 1 study to assess safety, tolerability, and pharmacokinetics of
 TR1801-ADC in patients with select solid tumors that express c-Met.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03859752
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03859752 through Pure Global AI's free database. This Phase 1 trial is sponsored by Tanabe Research Laboratories USA Inc and is currently Not yet recruiting. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.